An interventional study of Exercise in Lymphoma, sponsored by Biogipuzkoa Health Research Institute. Recruiting at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Biogipuzkoa Health Research Institute · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies in Lymphoma with a site in Spain — 25 open to participants now, 43 under way, 10 of them phase 3. Lymphoma · Spain.
Among the 143 studies in Lymphoma with a site in Spain, this one is the 42nd largest by planned enrollment of the 134 interventional ones that give a count, is one of 9 that started in 2024, is one of 4 with no phase, reaches primary completion later than 21 of the 42 other live ones, and was the 137th registered.
3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →25 of the 143 studies in Lymphoma with a site in Spain are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in Spain, United States, Italy
Ages 18+
ModeX Therapeutics, An OPKO Health Company · Sites in Spain, Australia, Israel
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Spain, Portugal
Ages 18+
ITM Solucin GmbH · Sites in Spain, United States, France
Ages 24 mo–18 yrs
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 54 · Phase 2 65 · Phase 3 33 · Phase 4 3
First in 1998; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 43 across 2,320 interventional studies indexed under Lymphoma.
Median enrollment 111 across the 134 interventional studies, 164 across the 8 observational. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 143 have an industry lead sponsor. The 10 most frequent:
Biogipuzkoa Health Research Institute is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Biogipuzkoa Health Research Institute has 1 study filed under Lymphoma — fewer than ten, so there is no comparison to draw.
13 of the studies in Lymphoma with a site in Spain that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
| NCT06084936Phase 3Hoffmann-La RocheA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | 2027-08-31 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT07914348Leukos Biotech S.L.Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphoma | 2026-12 |
Add all 13 to your calendar (.ics) → With an account.
Among the 143 studies in Lymphoma with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In people diagnosed with lymphoma receiving immunochemotherapy treatment, a combined exercise intervention, as opposed to the general recommendations, will achieve: 1.Improve cardiorespiratory fitness, strength, psychological well-being and quality of life. //2.Reduce fatigue//3.Reduce frailty
There is an association between some biological biomarkers with physical capacity and frailty.
In this study, the effectiveness of an individualized adjuvant exercise program will be analyzed in a homogeneous population of people diagnosed with lymphoma in active treatment. Taking into account the limited scientific evidence that currently exists in people affected by lymphoma and active treatment, the study could be of great relevance when it comes to providing scientific evidence in this very little field studied. The study will try to respond to the evident need to focus the research area on supervised exercise in people with lymphoma in a way innovative, with the aim of generating new hypotheses that overcome existing limitations and facilitate the introduction of this type of interventions into the health system. The present study will also analyze the effect of exercise from a gender perspective, an aspect not systematically studied until now, providing a new vision on the baseline differences and after intervention of a program based on of sex.
The study will include adults with lymphoma with special focus on the subanalysis of the group of patients equal or more than 70 years old. The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new exercise project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic. 30 people with lymphoma and treatment have been included in the Onkofrail study asset. The preliminary results of said pilot study have been used for the design of this new study, making adaptations, both in the recruitment time, as well as inclusion and exclusion criteria, which guarantee and optimize the correct research development.
Main objective:
The main objective is to assess whether a supervised (2 days/week) combined (resistance+aerobic interval training) exercise intervention, plus 2 days/week unsupervised for 20 weeks improves cardiorespiratory fitness (CRF) in people diagnosed with lymphoma undergoing chemotherapy, compared to a control group receiving only general recommendations.
Secondary objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The control group will receive the usual care and indications.
The interventional group will add a exercise program.
Other: Exercise
The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new PE project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic.
Cardiorespiratory fitness (CRF)
Measured by peak oxygen uptake (VO2peak) before starting chemotherapy treatment and after 20 weeks of intervention, using the cardiorespiratory exercise test.
Time frame: 20 weeks
Sociodemographic, etiological and clinical health variables (A)
Recruitment Center (Donostia University Hospital, Galdakao University Hospital , Alava University Hospital)
Time frame: 20 weeks
Sociodemographic, etiological and clinical health variables (B)
Birthdate.
Time frame: 20 weeks
Sociodemographic, etiological and clinical health variables (C)
Biological sex (man, woman, I prefer not to answer)
Time frame: 20 weeks
Sociodemographic, etiological and clinical health variables (D)
Gender (man, woman, non-binary or I prefer not to answer)
Time frame: 20 weeks
Sociodemographic, etiological and clinical health variables (E)
Educational level (no studies, elementary, high school, vocational training, university, I prefer not to answer, others)
Time frame: 20 weeks
Sociodemographic, etiological and clinical health variables (F)
Home composition (single person, lives with couple, lives with family, institutionalized, I prefer not to answer, others)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (A.1.)
Muscle power and fragility --\> SIT - TO STAND (STS) POWER: time to repeat the action 5 (sec)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (A.2.)
Muscle power and fragility --\> FRAILTY TRAIT TEST SCALE (FTS-5): BMI (kg/m)2; running time (sec); grip strength (kg); Progressive Romberg Test (positive/negative).
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (B.1.)
G8 Scale (0-17 pts)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (B.2.)
Fried Frailty Phenotype (0-5 pts)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (C)
Physical Condition: Modified Shuttle Walking Field Test (meters)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (D)
UPPER BODY MUSCLE STRENGTH (HANGRIP) (Newton)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (E)
Body composition --\> Height (cm); Weight (kg); Waist circumference (cm); hip circumference (cm); body mass index (kg/m2); fat free mass (kg and %); fat mass (kg and %); total body water (kg and %); phase angle (º); systolic blood pressure (mmHG); diastolic blood presure (mmHg); resistance (Ω); reactance (Ω).
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (F)
Physical activity level --\> Global Questionnaire on Physical Activity (GPAQ)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (G)
Sleep Quality --\> Epworth Sleepiness Scale (ESS EPWORTH) (0-24 pts)
Time frame: 20 weeks
Functionality and fragility variables at times T0, T1 and T2 (H)
Acelerometry (h/d)
Time frame: 20 weeks
Patient Reported Results (A)
Quality of Life Questionnaire --\> Hematological Malignancy - Patient Reported Outcome (HM-PRO) at times T0, T1 and T2 (Nothing, mild and serious)
Time frame: 20 weeks
3. Patient-reported results (PRO):
EORTC QLQ - FA13
Time frame: 20 weeks
Biomarkers
Inflammation (pg/ml or ng/ml), Hematological (pg/ml or ng/ml), Endocrine Nutritional (pg/ml or ng/ml), Immunosenescence (pg/ml or ng/ml),
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (A)
Gijon Scale (3-15 pts)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (B)
Basic Activity of Dialy Living (BADL) - Barthel Scale (0-10 pts)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (C)
Instrumental Activity of Dialy Livings (IADL) - Lawton Scale (0-8 pts)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (D)
Cognitive Function - Pfeiffer Test (0-10 pts)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (E)
Nutritional Status - Mini Nutritional Assessment Short-form (MNA.SFI) (0-14 pts)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (F)
Polypharmacy (number of chronica drug consumed by the participant)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (G)
Geriatric Syndromes - Immobility and pressure ulcers (Yes/No); instability and falls (Yes/No); urinary and faecal incontinence (Yes/No); dementia and acute confusional syndrome ( Yes//No); malnutrition (Yes/No); alterations in sight and hearing (Yes/No);constipation, faecal impaction (Yes/No);depression/insomnia (Yes/No)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (H)
Pain - Visual Analogue Scale (VAS) (0-10 pts)
Time frame: 20 weeks
Variables of Geriatric Assessment (VGA) comprehensive in patients (I)
Emotional Distress - Stress Thermometer (0-10 pts)
Time frame: 20 weeks
Treatment data and results after the intervention (T2) (A)
Treatment Suspension (Yes/No)
Time frame: 20 weeks
Treatment data and results after the intervention (T2) (B)
Dose Reduction (Yes/No)
Time frame: 20 weeks
Treatment data and results after the intervention (T2) (C)
Treatment percentage completed (%)
Time frame: 20 weeks
Treatment data and results after the intervention (T2) (D)
Treatment Completion (Yes/No)
Time frame: 20 weeks
Assessment of the intervention at T2 (A)
Adverse events associated with intervention (Number of adverse events)
Time frame: 20 weeks
Assessment of the intervention at T2 (B)
Satisfaction with the intervention (Yes/No)
Time frame: 20 weeks
Assessment of the intervention at T2 (C)
Adherence to the intervention (Yes/No)
Time frame: 20 weeks
Not enrolling at this site.
Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.
Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 29 months is below that.
Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biogipuzkoa Health Research Institute